EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial

M P Cliteur iD, A G van der Kolk, G Hannink, J Hofmeijer, Wmt Jolink, Cjm Klijn, Fhbm Schreuder iD

European Stroke Journal · 01.03.2024 · 9 (1) · 265-273

DOI: 10.1177/23969873231200686 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Stroke Journal, online erschienen am 01.03.2024. Verfasst von M P Cliteur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Interleukin 1 Receptor Antagonist Protein, Brain Injuries. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Heart Foundation, Swedish Orphan Biovitrum AB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammation plays a vital role in the development of secondary brain injury after spontaneous intracerebral haemorrhage (ICH). Interleukin-1 beta is an early pro-inflammatory cytokine and a potential therapeutic target.

Aim

To determine the effect of treatment with recombinant human interleukin-1 receptor antagonist anakinra on perihematomal oedema (PHO) formation in patients with spontaneous ICH compared to standard medical management, and investigate whether this effect is dose-dependent.

Methods

ACTION is a phase-II, prospective, randomised, three-armed (1:1:1) trial with open-label treatment and blinded end-point assessment (PROBE) at three hospitals in The Netherlands. We will include 75 patients with a supratentorial spontaneous ICH admitted within 8 h after symptom onset. Participants will receive anakinra in a high dose (loading dose 500 mg intravenously, followed by infusion with 2 mg/kg/h over 72 h; n = 25) or in a low dose (loading dose 100 mg subcutaneously, followed by 100 mg subcutaneous twice daily for 72 h; n = 25), plus standard care. The control group (n = 25) will receive standard medical management. Outcomes: Primary outcome is PHO, measured as oedema extension distance on MRI at day 7 ± 1. Secondary outcomes include the safety profile of anakinra, the effect of anakinra on serum inflammation markers, MRI measures of blood brain barrier integrity, and functional outcome at 90 ± 7 days.

Discussion

The ACTION trial will provide insight into whether targeting interleukin-1 beta in the early time window after ICH onset could ameliorate secondary brain injury. This may contribute to the development of new treatment options to improve clinical outcome after ICH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin 1 Receptor Antagonist ProteinBrain InjuriesHumansInterleukin-1betaNeuroinflammatory DiseasesProspective StudiesCerebral HemorrhageEdemaRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Intracerebral haemorrhageneuroinflammationoedemaprotocolrandomised trial

Substanzen

Interleukin-1betaInterleukin 1 Receptor Antagonist Protein

Autor:innen und Institutionen

  • Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.
  • Department of Clinical Neurophysiology, University of Twente, Enschede, The Netherlands.
  • Department of Neurology, Isala Hospital, Zwolle, The Netherlands.

ORCID-Profile: M P Cliteur, Fhbm Schreuder

Förderung

  • Dutch Heart Foundation
  • Swedish Orphan Biovitrum AB

Zitieren

APA

Cliteur, M. P., van der Kolk, A. G., Hannink, G., Hofmeijer, J., Jolink, W., Klijn, C., & Schreuder, F. (2024). Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial. European Stroke Journal, 9(1), 265-273. https://doi.org/10.1177/23969873231200686

Vancouver

Cliteur MP, van der Kolk AG, Hannink G, Hofmeijer J, Jolink W, Klijn C, et al. Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial. European Stroke Journal. 2024;9(1):265-273. doi:10.1177/23969873231200686

BibTeX
@article{Cliteur2024,
  author = {Cliteur, M P and van der Kolk, A G and Hannink, G and Hofmeijer, J and Jolink, Wmt and Klijn, Cjm and Schreuder, Fhbm},
  title = {Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial},
  journal = {European Stroke Journal},
  year = {2024},
  volume = {9},
  number = {1},
  pages = {265--273},
  doi = {10.1177/23969873231200686}
}
Kostenlos starten →